Glycoform and Net Charge Heterogeneity in gp120 Immunogens Used in HIV Vaccine Trials

Abstract excerpt

BACKGROUND: The RV144 clinical trial showed for the first time that vaccination could provide modest but significant protection from HIV-1 infection. To understand the protective response, and to improve upon the vaccine's efficacy, it is important to define the structure of the immunogens used in the prime/boost regimen. Here we examined the heterogeneity in net charge, attributable to glycoform variation, of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to HIV/AIDS drug development and treatment
• Share to HIV Research and Treatment
• Share to Immunotherapy and Immune Responses